Curated News
By: NewsRamp Editorial Staff
September 18, 2026

Silo Pharma Secures USPTO Allowance for PTSD Therapeutic SPC-15

Discuss on Substack
Original Source

TLDR

  • Silo Pharma's USPTO allowance for SPC-15 strengthens its PTSD patent portfolio, offering a strategic edge in the biopharma market.
  • The USPTO issued a Notice of Allowance for Silo Pharma's SPC-15 patent, covering intranasal compositions and methods to prevent stress-induced fear and anxiety.
  • Silo Pharma's SPC-15 patent allowance advances a potential intranasal treatment for PTSD, aiming to improve lives affected by stress-induced disorders.
  • Silo Pharma's SPC-15, an intranasal PTSD therapy, received a U.S. patent allowance, following a similar patent grant in Japan earlier this year.

Impact - Why it Matters

This patent allowance is a significant milestone for Silo Pharma and the PTSD treatment landscape. PTSD affects millions worldwide, and current therapies often have limited efficacy or undesirable side effects. By securing U.S. patent protection for SPC-15, Silo Pharma strengthens its intellectual property position, which could attract investors and partners, accelerating the development of a novel intranasal treatment. The allowance also complements the earlier Japanese patent, signaling global recognition of the innovation. For patients, this progress offers hope for a new therapeutic option that targets stress-induced fear and anxiety. Moreover, it underscores the importance of protecting proprietary research in the competitive biopharmaceutical industry, potentially paving the way for further advancements in CNS disorders.

Summary

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, targeting post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes both composition and method claims for Silo’s proprietary approach to preventing or delaying stress-induced behavioral responses. This U.S. allowance follows a corresponding patent issued earlier this year by the Japan Patent Office, underscoring the global intellectual property strategy for SPC-15.

A Notice of Allowance means the USPTO has completed its examination and determined that the application meets all requirements for patentability, and the patent is expected to be granted shortly. Silo Pharma emphasized that this U.S. patent protection is a critical component of its strategy as it advances SPC-15 development for PTSD, strengthening its biopharmaceutical intellectual property portfolio of issued and allowed patents. The company’s broader pipeline includes innovative programs such as SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer’s disease and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories. For more details, visit the full press release at https://ibn.fm/Hh4Z6 or the company’s website at silopharma.com. The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Secures USPTO Allowance for PTSD Therapeutic SPC-15

Blockchain registration record for this content